0HIY.LAtara Biotherapeutics Inc

Über

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

www.atarabio.com

Kennzahlen

Marktkapitalisierung

102.37M

EPS

2.61

Dividendenrendite

0.00%

Beta

0.11

KBV

-5.86

EK-Rendite

-84.9%

Sektor

Healthcare

Branche

Medical - Pharmaceuticals

CEO

Anhco Nguyen

Mitarbeiter

14

IPO-Datum

2018-01-29

Land

US